Accreditation Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Dana-Farber Cancer Institute. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Objectives

Upon completion of this activity, participants will be able to:

  1. Describe current research on the etiology, pathogenesis, metastasis and treatment of head and neck cancer;
  2. Apply innovative therapeutic approaches to the treatment of head and neck cancer patients with particular emphasis on immunotherapy and precision medicine;
  3. Identify the translational gap whereby advances in research are not translated into clinical applications that directly benefit patient health.

Target Audience

Target audience:

  • Otolaryngology / Head and Neck Surgery
  • Medical Oncology
  • Radiation Oncology
  • Surgical Oncology
  • Oral and Maxillofacial Surgery
  • Oral and Maxillofacial Radiology
  • Oral and Maxillofacial Pathology
  • Dental Public Health
  • Head & Neck Cancer Researchers

Faculty Disclosure

All planners, speakers, authors, and reviewers involved with content development for continuing education activities provided by Boston University are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.